Evotec And Arix Bridge Gap With Latest Cancer Funding

Arix Biosciences and Evotec AG have formed an academic partnership to accelerate research discoveries at the Fred Hutchison Cancer Research Center.

SC1805_Golden Gate Bridge_136918865_1200.jpg

The German biotech Evotec AG is to use its BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) model, an integrated fund and reward model, to form a new partnership withArix BioSciences PLC, LAB591. Together with the Fred Hutchinson Cancer Research Center, the three partners will jointly select promising research projects from the laboratories of the cancer research center, which is based in Seattle. The initial term of LAB591 is five years.

Once a research project has been chosen, Evotec will collaborate with Fred Hutchison on the research, seed-funded by Arix. Depending...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip

China’s Biotechs Were The Small-Cap Rising Stars In H1 2025

 

The list of small-cap companies with the fastest-rising share prices so far this year is dominated by Chinese companies, underscoring their growing contribution to the global biopharma ecosystem.

In Brief: Soleno To Raise $200m To Boost Vykat XR Launch

 
• By 

Soleno Therapeutics will raise about $200m gross proceeds from an offering of 2.35m of its common stock to fund the commercialization of Vykat XR, which became the first drug for Prader-Willi syndrome to gain US approval on March 26.

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.